Developer docs
API playgroundTry for free, no card

Search company profiles

ProteinQure

Full company profile

uuid0000e9k

Namestring
ProteinQure
Legal namestring
ProteinQure Inc.
Websiteurl
proteinqure.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
computational peptide design, peptide-drug conjugates, AI drug discovery, targeted drug delivery, clinical-stage biotechnology
Industry8 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Computational Peptide Therapeutics & Drug Discovery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharma Collaboration & Partnership Revenue
TypeProfessional Services
Description

Quoted/scope-based partnerships with pharmaceutical companies structured around lead optimization, AI-guided library design, and de novo peptide design. Company has historically disclosed that partnerships represented about 50% of its work, with pharma BD/strategy relationships including AstraZeneca, Daiichi Sankyo, NeuroDerm, Pioneering Medicines, Twist Bioscience, and Johnson & Johnson.

proteinqure.com
2Non-Dilutive Grant Funding
TypeManaged Services
Description

Receipt of non-dilutive funding from Canadian government programs, including FedDev Ontario ($1.8M in May 2026), Genome Canada / Ontario Genomics (~$2.5M in April 2026), National Research Council of Canada IRAP, Ontario Center for Innovation (OCI), and the Canada Digital Adoption Program (CDAP). These fund internal drug discovery projects.

proteinqure.com
3Equity Financing (Pre-Commercial)
TypeSubscription Recurring
Description

Clinical-stage company with no product revenue; capitalization is driven by equity rounds (e.g., $4M seed in 2019, $11M Series A in May 2025, totaling $16M) intended to fund PQ203 Phase 1 trial and pipeline expansion in neurology and nephrology.

proteinqure.com
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1ProteinStudio™
Description

Proprietary computational platform integrating machine learning, structural biology, and atomic-level simulations to design therapeutic peptides using thousands of non-natural amino acids for tissue-specific delivery and access to novel target classes.

proteinqure.com
Core offering1 text field

ProteinQure designs AI-engineered peptide-based therapeutics and targeted drug-delivery systems using its proprietary ProteinStudio™ computational platform, which integrates machine learning, structural biology, and petascale molecular simulations to create de novo peptides and peptide-drug conjugates incorporating non-natural amino acids. The company offers three core partnership tracks to pharmaceutical companies—Lead Optimization, AI-Guided Library Design, and De Novo Peptide Design—and is independently advancing a clinical-stage pipeline led by PQ203, a SORT1-targeting peptide-drug conjugate currently in Phase I trials for advanced solid tumors including triple-negative breast cancer.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ProteinQure operates a platform-plus-pipeline architecture: a single proprietary computational platform called ProteinStudio™ sits at the core and powers both internal pipeline assets and partnered drug discovery programs. Built on ProteinStudio are multiple therapeutic products spanning tissue-specific delivery, including the lead clinical-stage peptide-drug conjugate PQ203 (Phase I for advanced solid tumors including triple-negative breast cancer), the SORT1 Delivery System as a modular targeted-delivery technology, a preclinical peptide-siRNA conjugate program for glioblastoma multiforme, and a BBB Shuttle peptide conjugate program. ProteinStudio also underpins PQ Librarian, a public-facing AI-driven peptide library scoring tool, and supports partnered programs with companies such as AstraZeneca, Daiichi Sankyo, NeuroDerm, Pioneering Medicines, Twist Bioscience, and Johnson & Johnson across lead optimization, AI-guided library design, and de novo peptide design.

Product and service4 records
1ProteinStudio™
CategoryCore computational platform
Description

ProteinQure's proprietary integrated computational platform combining machine learning, structural biology, and atomic-level molecular simulations on petascale supercomputers. Designs de novo peptides and peptide-drug conjugates across a chemical space of thousands of non-natural amino acids and supports lead optimization, AI-guided library design, and de novo peptide design for therapeutic payload delivery. Used internally for ProteinQure's pipeline and externally to deliver partnership engagements with global biopharmaceutical companies.

2PQ203
CategoryLead clinical-stage therapeutic asset
Description

First-in-class AI-designed peptide-drug conjugate composed of a Sortilin (SORT1)-targeting peptide conjugated to the cytotoxic payload MMAE. Currently in a Phase I clinical trial (NCT07190469) in Canada and the United States for advanced solid tumors, including triple-negative breast cancer; granted FDA Fast Track designation. Designed via ProteinStudio™ and validated in 17+ in vivo models.

3SORT1 Delivery System
CategoryTargeted-delivery technology platform
Description

Computationally designed, high-affinity SORT1-targeting peptides used as a modular delivery platform for SORT1-overexpressing tumors (including TNBC, colon, and ovarian cancer). Enables receptor-mediated internalization and lysosomal delivery of cytotoxic agents, radioisotopes, and oligonucleotides via peptide-drug, peptide-radioisotope, and peptide-oligonucleotide conjugates.

4PQ Librarian
CategoryPublic AI tool
Description

AI-driven peptide library scoring tool that combines Large Language Models with predictive neural networks trained on peptide-receptor interaction data. Accepts a target protein antigen sequence and outputs color-coded hit-potential scores (green/yellow/red) for ProteinQure's proprietary and standard peptide libraries. Validated on 20+ proprietary targets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1PeptiDream
TypeDirect peer
Description

Japanese peptide discovery company operating a platform for identifying non-standard peptide therapeutics against a wide range of targets, with multiple pharma partnerships — directly comparable in peptide-platform-plus-partnership business model.

TypeEmerging player
Description

AI-first generative biology company designing novel proteins and peptides de novo using machine learning. Comparable in combining generative AI with protein/peptide therapeutic design, though with broader scope.

TypeDirect peer
Description

AI-driven drug discovery company combining machine learning, high-throughput biology, and pharma partnerships to advance internal and partnered programs — directly comparable AI-for-drug-discovery positioning.

TypeEmerging player
Description

AI protein engineering company using generative models to design novel proteins and biologics — closely comparable in applying generative AI to protein/peptide design with a partnership-oriented GTM.

TypeEmerging player
Description

AI-driven biotech developing nucleic acid and protein therapeutics using a generative molecular design platform — comparable as an AI-driven preclinical/early-clinical biotech with similar modality breadth.

TypeDirect peer
Description

Techbio company combining high-throughput experimentation, automation, and AI to discover and develop novel therapeutics at scale — directly comparable as an AI-native drug discovery platform.

TypeEmerging player
Description

AI-first protein design company using generative models and high-throughput experimentation to engineer novel proteins, with a pharma partnership GTM — directly comparable in AI protein/peptide design with a partnership business model.

8Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed AI drug discovery company applying deep learning to predict protein structures and design novel therapeutics. Comparable as a deep-tech AI-first drug design platform with substantially greater capital backing.

TypeEmerging player
Description

Clinical-stage biotech developing macrocyclic peptide therapeutics against difficult-to-drug targets including oncology — comparable as a peptide-platform biotech with oncology focus and Edward Garmey's prior affiliation.

TypeDirect peer
Description

Clinical-stage biotech developing bicyclic peptide-drug conjugates and other targeted therapeutics using computationally designed peptides. Most direct comparable given shared PDC modality, oncology focus, and platform-plus-pipeline architecture.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProteinQure

Computational Peptide Therapeutics & Drug Discovery Platformproteinqure.com

ProteinQure firmographics

Firmographics
Name
ProteinQure
Legal name
ProteinQure Inc.
Website
https://proteinqure.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

ProteinQure industry classification

Industry
Product category
Computational Peptide Therapeutics & Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational peptide design
  • Peptide-drug conjugates
  • AI drug discovery
  • Targeted drug delivery
  • Clinical-stage biotechnology

Where ProteinQure is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Markets served

ProteinQure business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharma Collaboration & Partnership Revenue: Quoted/scope-based partnerships with pharmaceutical companies structured around lead optimization, AI-guided library design, and de novo peptide design. Company has historically disclosed that partnerships represented about 50% of its work, with pharma BD/strategy relationships including AstraZeneca, Daiichi Sankyo, NeuroDerm, Pioneering Medicines, Twist Bioscience, and Johnson & Johnson.
  2. Non-Dilutive Grant Funding: Receipt of non-dilutive funding from Canadian government programs, including FedDev Ontario ($1.8M in May 2026), Genome Canada / Ontario Genomics (~$2.5M in April 2026), National Research Council of Canada IRAP, Ontario Center for Innovation (OCI), and the Canada Digital Adoption Program (CDAP). These fund internal drug discovery projects.
  3. Equity Financing (Pre-Commercial): Clinical-stage company with no product revenue; capitalization is driven by equity rounds (e.g., $4M seed in 2019, $11M Series A in May 2025, totaling $16M) intended to fund PQ203 Phase 1 trial and pipeline expansion in neurology and nephrology.

Go-to-market motion2 records

ProteinQure product offering

Product offering

Core offering

ProteinQure designs AI-engineered peptide-based therapeutics and targeted drug-delivery systems using its proprietary ProteinStudio™ computational platform, which integrates machine learning, structural biology, and petascale molecular simulations to create de novo peptides and peptide-drug conjugates incorporating non-natural amino acids. The company offers three core partnership tracks to pharmaceutical companies—Lead Optimization, AI-Guided Library Design, and De Novo Peptide Design—and is independently advancing a clinical-stage pipeline led by PQ203, a SORT1-targeting peptide-drug conjugate currently in Phase I trials for advanced solid tumors including triple-negative breast cancer.

Product overview

ProteinQure operates a platform-plus-pipeline architecture: a single proprietary computational platform called ProteinStudio™ sits at the core and powers both internal pipeline assets and partnered drug discovery programs. Built on ProteinStudio are multiple therapeutic products spanning tissue-specific delivery, including the lead clinical-stage peptide-drug conjugate PQ203 (Phase I for advanced solid tumors including triple-negative breast cancer), the SORT1 Delivery System as a modular targeted-delivery technology, a preclinical peptide-siRNA conjugate program for glioblastoma multiforme, and a BBB Shuttle peptide conjugate program. ProteinStudio also underpins PQ Librarian, a public-facing AI-driven peptide library scoring tool, and supports partnered programs with companies such as AstraZeneca, Daiichi Sankyo, NeuroDerm, Pioneering Medicines, Twist Bioscience, and Johnson & Johnson across lead optimization, AI-guided library design, and de novo peptide design.

Differentiator

Problem solved

Functional benefit

Brands

  • ProteinStudio™: Proprietary computational platform integrating machine learning, structural biology, and atomic-level simulations to design therapeutic peptides using thousands of non-natural amino acids for tissue-specific delivery and access to novel target classes.

Products and services

  • ProteinStudio™ ProteinQure's proprietary integrated computational platform combining machine learning, structural biology, and atomic-level molecular simulations on petascale supercomputers. Designs de novo peptides and peptide-drug conjugates across a chemical space of thousands of non-natural amino acids and supports lead optimization, AI-guided library design, and de novo peptide design for therapeutic payload delivery. Used internally for ProteinQure's pipeline and externally to deliver partnership engagements with global biopharmaceutical companies.
  • PQ203 First-in-class AI-designed peptide-drug conjugate composed of a Sortilin (SORT1)-targeting peptide conjugated to the cytotoxic payload MMAE. Currently in a Phase I clinical trial (NCT07190469) in Canada and the United States for advanced solid tumors, including triple-negative breast cancer; granted FDA Fast Track designation. Designed via ProteinStudio™ and validated in 17+ in vivo models.
  • SORT1 Delivery System Computationally designed, high-affinity SORT1-targeting peptides used as a modular delivery platform for SORT1-overexpressing tumors (including TNBC, colon, and ovarian cancer). Enables receptor-mediated internalization and lysosomal delivery of cytotoxic agents, radioisotopes, and oligonucleotides via peptide-drug, peptide-radioisotope, and peptide-oligonucleotide conjugates.
  • PQ Librarian AI-driven peptide library scoring tool that combines Large Language Models with predictive neural networks trained on peptide-receptor interaction data. Accepts a target protein antigen sequence and outputs color-coded hit-potential scores (green/yellow/red) for ProteinQure's proprietary and standard peptide libraries. Validated on 20+ proprietary targets.

Companies that use ProteinQure

Customer profile

Ideal customer profiles2 records

ProteinQure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

ProteinQure partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

ProteinQure competitors and assessment

Company assessment

Direct peers

  • PeptiDream: Japanese peptide discovery company operating a platform for identifying non-standard peptide therapeutics against a wide range of targets, with multiple pharma partnerships — directly comparable in peptide-platform-plus-partnership business model.
  • Insitro: AI-driven drug discovery company combining machine learning, high-throughput biology, and pharma partnerships to advance internal and partnered programs — directly comparable AI-for-drug-discovery positioning.
  • Recursion: Techbio company combining high-throughput experimentation, automation, and AI to discover and develop novel therapeutics at scale — directly comparable as an AI-native drug discovery platform.
  • Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide-drug conjugates and other targeted therapeutics using computationally designed peptides. Most direct comparable given shared PDC modality, oncology focus, and platform-plus-pipeline architecture.

Emerging players

  • Generate Biomedicines: AI-first generative biology company designing novel proteins and peptides de novo using machine learning. Comparable in combining generative AI with protein/peptide therapeutic design, though with broader scope.
  • Cradle Bio: AI protein engineering company using generative models to design novel proteins and biologics — closely comparable in applying generative AI to protein/peptide design with a partnership-oriented GTM.
  • Entos Pharmaceuticals: AI-driven biotech developing nucleic acid and protein therapeutics using a generative molecular design platform — comparable as an AI-driven preclinical/early-clinical biotech with similar modality breadth.
  • Nabla Bio: AI-first protein design company using generative models and high-throughput experimentation to engineer novel proteins, with a pharma partnership GTM — directly comparable in AI protein/peptide design with a partnership business model.
  • Circle Pharma: Clinical-stage biotech developing macrocyclic peptide therapeutics against difficult-to-drug targets including oncology — comparable as a peptide-platform biotech with oncology focus and Edward Garmey's prior affiliation.

Broad incumbents

  • Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to predict protein structures and design novel therapeutics. Comparable as a deep-tech AI-first drug design platform with substantially greater capital backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ProteinQure social profiles

Digital presence

ProteinQure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProteinQure leadership team

Management profile

Number of profiles

Profiles10 records

ProteinQure funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProteinQure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProteinQure

What does ProteinQure do?

ProteinQure designs AI-engineered peptide-based therapeutics and targeted drug-delivery systems using its proprietary ProteinStudio™ computational platform, which integrates machine learning, structural biology, and petascale molecular simulations to create de novo peptides and peptide-drug conjugates incorporating non-natural amino acids. The company offers three core partnership tracks to pharmaceutical companies—Lead Optimization, AI-Guided Library Design, and De Novo Peptide Design—and is independently advancing a clinical-stage pipeline led by PQ203, a SORT1-targeting peptide-drug conjugate currently in Phase I trials for advanced solid tumors including triple-negative breast cancer.

Is ProteinQure a public or private company?

ProteinQure is a private company. It is classified as venture growth investor backed and is currently operating.

When was ProteinQure founded?

ProteinQure was founded in 2018. It employs 11 to 50 people.

Where is ProteinQure based?

ProteinQure is headquartered in Toronto, Canada, in the North America region.

How does ProteinQure make money?

Three revenue lines are on record. Pharma Collaboration & Partnership Revenue is the primary driver. The others are non-Dilutive Grant Funding and equity Financing (Pre-Commercial).

Who are ProteinQure's main competitors?

Direct peers on record are PeptiDream, Insitro, Recursion and Bicycle Therapeutics. Emerging players are Generate Biomedicines, Cradle Bio, Entos Pharmaceuticals, Nabla Bio and Circle Pharma. Isomorphic Labs is listed as a broad incumbent.

Does ProteinQure have an API?

No public API is recorded for ProteinQure.

What industry is ProteinQure in?

ProteinQure's product category is Computational Peptide Therapeutics & Drug Discovery Platform. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BetaKitQuantum chemistry for drug discovery still hasn’t had its “ChatGPT moment,” biotech founder saysProteinQure co-founder Mark Fingerhuth stated at Creative Destruction Lab's Super Session during Toronto Tech Week that quantum chemistry has not yet had its 'ChatGPT moment' in drug discovery, arguing the bottleneck is 'messy biology experiments' rather than molecular simulation accuracy. The Toronto-based biotech startup has pivoted from quantum computing to classical algorithms and AI, which enabled it to advance an AI-designed peptide therapeutic to Phase 1 clinical trial for breast and brain cancers. Xanadu founder and CEO Christian Weedbrook, who spoke on the preceding panel, had offered a contrasting view, describing quantum chemistry as potentially 'the lowest-hanging fruit' for quantum computing.Digital JournalToronto Tech Week puts global growth under the microscopeToronto Tech Week featured panels on global expansion and an AI funding announcement. Minister Evan Solomon announced $16.5 million for 13 Greater Toronto Area companies through the Regional Artificial Intelligence Initiative. The funding aims to move AI from research to economic use, with deployment and talent as key challenges.UtorontoA Better Way to Build Cancer Drugs?Doctors at the Princess Margaret Cancer Centre in Toronto began human trials for PQ203, an experimental drug developed by ProteinQure, aiming to treat triple-negative breast cancer. If successful, PQ203 could become the first in a new class of cancer treatments, potentially reaching the market in five years. ProteinQure's approach to drug development focuses on using artificial intelligence to design new drugs from the ground up, representing a significant innovation in the biotech field.Business Wire BlogProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track DesignationProteinQure received FDA and Health Canada clearance to start a Phase I trial of PQ203 in the U.S. and Canada, with the FDA granting Fast Track designation for triple negative breast cancer. The trial will use an accelerated titration design to identify optimal dosing, and is expected to begin at Princess Margaret Cancer Centre in Toronto.Pulse 2.0ProteinQure: $11 Million Series A Raised For Computational Peptide TherapeuticsProteinQure closed an $11 million Series A led by Heron Rock Fund, bringing total funding to $16 million. The proceeds will support its first clinical trial for PQ203, a peptide-drug conjugate for triple-negative breast cancer, with a multicenter phase 1 trial opening in Q3 2025.PatsnapProteinQure Secures $11M to Advance AI-Designed Peptide-Drug Conjugate to Clinical TrialsProteinQure has secured $11 million in Series A funding to advance its AI-designed peptide-drug conjugate, PQ203, into clinical trials. The development aims to treat tumors resistant to traditional therapies, with a Phase I trial planned in the US and Canada.Financial PostProteinQure Raises Series A Financing to Advance First AI-Designed Peptide Therapeutic into Clinical TrialsProteinQure Inc. announced an $11 million Series A financing round to support the clinical trial of its peptide therapeutic PQ203 for triple-negative breast cancer (TNBC). The funding will also enable the development of additional pipeline programs in neurology and nephrology, with a clinical trial expected to open in late 2025 across North American cancer centers.LinkedInProteinQure raises $11M for AI peptide medicinesProteinQure closed an $11M Series A led by Heron Rock Fund and Golden Ventures. The funding will accelerate its AI-designed peptide therapeutic into the clinic and expand its pipeline. The company cites investor confidence in its physics-driven, AI-enabled strategy for tissue-specific delivery.PharmiWeb.comProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACRProteinQure announced a peptide drug conjugate targeting SORT1 showed remarkable efficacy in patient-derived xenograft models of triple-negative breast cancer. The data will be presented at AACR, and the company plans to move forward with IND-enabling studies and its first clinical trial.RadioinkBiotech Podcast ‘First In Human’ Getting Its Second SeasonClinical trial manager Vial is launching the second season of its biotech podcast, 'First in Human,' with a premiere date of September 5. The new season will feature interviews with industry leaders such as executives from ONL Therapeutics, ProteinQure, and LatchBio to discuss breakthroughs and challenges in the sector.